We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Pomalidomide Plus Low-Dose Dexamethasone in Relapsed/Refractory Multiple Myeloma Patients: Results of the Real-World "POWERFUL" Study.
- Authors
Terpos, Evangelos; Repousis, Panagiotis; Lalayanni, Chrysavgi; Hatjiharissi, Evdoxia; Assimakopoulou, Theodora; Vassilopoulos, Georgios; Pouli, Anastasia; Spanoudakis, Emmanouil; Michalis, Eurydiki; Pangalis, Gerassimos; Ntanasis-Stathopoulos, Ioannis; Poziopoulos, Christos; Kyrtsonis, Marie-Christine; Pappa, Vasiliki; Symeonidis, Argiris; Georgopoulos, Christos; Zikos, Panagiotis M.; Gavriatopoulou, Maria; Papadaki, Helen A.; Dadakaridou, Magdalini
- Abstract
The "POWERFUL" multicenter, retrospective, and prospective study investigated the effectiveness of pomalidomide plus low-dose dexamethasone (POM/LoDex) therapy in relapsed/refractory multiple myeloma in routine care in Greece. Ninety-nine eligible adult patients treated with POM/LoDex according to the approved label after having received ≥2 prior therapies, including lenalidomide and bortezomib, were consecutively enrolled between 16 November 2017 and 21 February 2019 in 18 hematology departments. Fifty patients (50.5%) started POM/LoDex as third-line treatment. During the treatment period (median: 8.3 months; range: 0.3–47.6 months), the median POM dose was 4 mg/day, and 31.3% of the patients received additional antimyeloma agents. The overall response rate was 32.3%. During a median follow-up period of 13.8 months (Kaplan–Meier estimate), the median progression-free survival (PFS) was 10.5 months (95% CI: 7.4–14.4). The PFS was not significantly different between patients receiving POM/LoDex in the third versus later line of therapy, nor between patients receiving concomitant antimyeloma therapy versus POM/LoDEx doublet. During the prospective safety data collection period (median: 7.6 months) among patients with prospective follow-up (N = 75), POM-related adverse event incidence rate was 42.7% (serious: 18.7%; grade ≥ 3 hematological POM-related adverse events: 8.0%). Only neutropenia (13.3%) was reported at a frequency ≥10%. In conclusion, in this real-world study, POM/LoDex displayed a long PFS with no new safety signals emerging.
- Subjects
GREECE; MULTIPLE myeloma; DEXAMETHASONE; PROGRESSION-free survival; ACQUISITION of data
- Publication
Journal of Clinical Medicine, 2021, Vol 10, Issue 7, p1509
- ISSN
2077-0383
- Publication type
Article
- DOI
10.3390/jcm10071509